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ABSTRACT
Intratumoral heterogeneity (ITH) is a prominent feature of kidney cancer. It is 
not known whether it has utility in finding associations between protein expression 
and clinical parameters. We used ITH that is detected by immunohistochemistry 
(IHC) to aid the association analysis between the loss of SWI/SNF components and 
clinical parameters.160 ccRCC tumors (40 per tumor stage) were used to generate 
tissue microarray (TMA). Four foci from different regions of each tumor were selected. 
IHC was performed against PBRM1, ARID1A, SETD2, SMARCA4, and SMARCA2. 
Statistical analyses were performed to correlate biomarker losses with patho-clinical 
parameters. Categorical variables were compared between groups using Fisher’s 
exact tests. Univariate and multivariable analyses were used to correlate biomarker 
changes and patient survivals. Multivariable analyses were performed by constructing 
decision trees using the classification and regression trees (CART) methodology. IHC 
detected widespread ITH in ccRCC tumors. The statistical analysis of the “Truncal 
loss” (root loss) found additional correlations between biomarker losses and tumor 
stages than the traditional “Loss in tumor (total)”. Losses of SMARCA4 or SMARCA2 
significantly improved prognosis for overall survival (OS). Losses of PBRM1, ARID1A 
or SETD2 had the opposite effect. Thus “Truncal Loss” analysis revealed hidden links 
between protein losses and patient survival in ccRCC. 
INTRODUCTION
What is intratumoral heterogeneity (ITH)?
One or a few cancerous cells with a few founding 
mutation(s) are the origins of tumors, then during tumor 
development additional mutations occurred to aid 
progression [1]. Consequently in many cancers different 
regions of a tumor share the same founding mutations 
but have different mutations that happened later. This 
regionally mixed mutational landscape is defined as 
Intratumoral Heterogeneity (ITH). ITH was discovered 
in many types of cancers including leukemia [2], 
glioblastoma [3], colon [4], pancreatic [5], ovarian [6], 
breast [7] and clear cell renal cell carcinoma (ccRCC) 
cancers [8, 9]. ITH suggest that tumor development occurs 
in a branched fashion instead of a linear one.
ITH and mutations in ccRCC
In ccRCC the loss of function of von-Hippel Lindau 
tumor suppressor (VHL) happens in around 80% of tumors. 
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It is inactivated through DNA mutations or promoter 
hypermethylation, and it is the founding mutation for 
ccRCC [10]. The familial VHL syndrome, which includes 
ccRCC as one of the lesions, is caused by germline VHL 
mutations. In recent years, large-scale sequencing studies 
identified additional mutated tumor suppressors [11–13]. 
Around 40% of ccRCC tumors were found to harbor 
mutations in polybromo-1 (PBRM1), a component of a 
SWI/SNF chromatin-remodeling complex [11]. In addition, 
10–15% of ccRCC tumors have inactivating mutations in 
either BRCA1-associated protein 1 (BAP1) or SET domain 
containing 2 (SETD2), a histone deubiquitinase and a 
histone methyltransferase respectively [12]. 
Gerlinger et al discovered that ITH was very 
prevalent in ccRCC [9]. They also identified convergent 
phenotypic evolution. In the same tumor, distinct 
mutations at different parts of the tumor could inactivate 
the same tumor suppressor genes such as SETD2, 
Phosphatase And Tensin Homolog (PTEN), and Lysine 
Demthylase 5C (KDM5C/JARID1C). In their analysis of 
eight kidney cancer samples, only chromosome 3p loss 
and VHL aberrations were present in all the cases. They 
were called truncal losses (root and ubiquitous losses) 
[8]. In tumors with PBRM1 mutations, half of them were 
truncal [8]. 
Can ITH be examined by IHC? can ITH be 
useful in predicting clinical outcome?
The ITH in ccRCC was primarily studied with Next 
Gen Sequencing (NGS). It provided high quality data and 
great resolution, but it is expensive and labor intensive. 
Consequently the number of the analyzed samples is 
small which prevented statistical analysis to correlate with 
clinical parameters. We investigated whether IHC could 
successfully characterize ITH. We further investigated 
whether the ITH analysis at a much larger scale could 
reveal hidden correlations between the loss of biomarkers 
and clinical parameters.
RESULTS
Immunohistochemical analysis of ccRCC foci on 
tissue microarray (TMA)
The demographic, pathological and clinical 
parameters of the ccRCC patients we selected for this 
study are presented in Table 1. We excised four foci from 
different areas from each tumor to construct TMA. In our 
previous publication we examined the specificity of the 
antibodies with cells expressing shRNA against target 
proteins and found them to be specific [14]. In addition 
many of these antibodies revealed expression losses when 
mutations in the target genes were detected [15–19]. With 
validated antibodies we stained five sets of the TMA. We 
found that all five proteins were stained primarily in the 
nucleus (Figure 1). This is consistent with the known roles 
of these proteins as chromatin regulators.
The summary of protein expression losses in 
tumors and foci
To be consistent with rule on DNA mutation calling 
in tumors, we decided that if the expression of a marker 
was gone in one focus out of four foci from a tumor, then 
that tumor had a loss of expression of that marker. The 
detailed tally of the protein expression loss was described 
before [14]. We found that 31% of tumors lost expression 
of PBRM1. In addition, 51% of them lost ARID1A, 14% 
of them lost SETD2, 15% of them lost SMARCA4, and 
38% of them lost SMARCA2 expressions (Table 2). If the 
loss of protein expression was calculated with foci, 17%, 
32%, 6.1%, 6.9% and 22% of foci lost the expressions of 
PBRM1, ARID1A, SETD2, SMARCA4, and SMARCA2 
respectively (Table 2).
The truncal loss analysis revealed hidden links 
between biomarker losses and tumor stages
The relationships between different molecular 
events can be inferred by clonal ordering [20], and a 
phylogenetic tree can be constructed to represent this. If 
a molecular event is a founding one, it will be present in 
most regions of a tumor. We call it a truncal (early or root) 
change. Conversely, if a molecular event arises late during 
tumor development, this change might be only detected in 
one or two foci. We call it a branch (late) change. Tumor 
#7 from the stage 1 group provided an example: the 
SMARCA2 loss was a truncal event, PBRM1 loss was a 
branch event, while ARID1A and SMARCA4 losses were 
branch events that happened even later (Figure 2A). 
Next we examined the truncal changes that occurred 
in these tumors. Each tumor stage was represented by 
40 tumors, and 23, 23, 26, 30 cases from stage 1 to 4 had 
protein expression losses respectively (Figure 2B). For 
brevity, we called the protein losses A (ARID1A loss), P 
(PBRM1 loss), S (SETD2 loss), G (SMARCA4/BRG1 
loss), M (SMARCA2/BRM loss). We grouped the protein 
losses into three camps: Only Truncal Loss (it includes 
tumors with truncal loss that is the only truncal loss), 
Truncal Loss (Total) (it includes tumors with truncal loss, 
either alone or in combination), or the Loss in Tumor 
(Total) (it includes all the tumors with protein losses). 
We then used Fisher’s exact tests to examine whether 
the biomarker losses were statistically associated with 
high tumor stage (stage 4). In the case of PBRM1, the 
loss frequencies increased with stage and the associations 
between truncal loss groups with high stage had much 
smaller p values than that of Loss in Tumor (Total), which 
suggested higher confidence (Figure 2C). For SMARCA2, 
the loss frequency decreased when stage increased. The 
truncal loss groups had very small p values, while that of 
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Loss in Tumor (Total) was a borderline 0.05 (Figure 2C). 
For ARID1A, the higher stages had more protein losses, 
but just the Only Truncal Loss group had a statistically 
significant association with high stage (Figure 2C). 
SMARCA4 loss did not show any statistically significant 
association with high stage (Figure 2C). As for SETD2, 
only the Truncal Loss (Total) group was significantly 
associated with high stage (p = 0.032) (Figure 2C). 
The truncal loss analysis reveals hidden 
associations between protein losses and patient 
survival
It is not known whether truncal losses of protein 
markers would reveal statistically different associations 
with patient survival than those of total losses. Cox 
proportional hazards (PH) models were utilized to 
correlate recurrence-free survival (RFS) with biomarker 
losses.  For the protein losses, two groups of protein losses 
were used for analysis: one included all the truncal losses 
(Proteinname.Truncal). The other one included all the 
protein losses (Proteinname.Total). In univariate analyses, 
SETD2.Total, SMARCA2.Total, SMARCA4.Truncal, and 
SMARCA2.Truncal displayed a significant association with 
RFS with p values near or below 0.05 while SMARCA4.
Total and SETD2.Truncal showed marginally significant 
associations (Table 3). In further multivariable analysis, 
only SETD2.Total’s association with RFS remained 
statistically significant. The Kaplan-Meier curve showed 
that patients that lost SETD2 staining in tumors had shorter 
Table 1: Characteristics of ccRCC patients included in this study
Number of patients 160
































Clear Cell only 160
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RFS (Figure 3). Thus, most of the markers do not appear to 
be associated with RFS and the ITH analysis did not help.
The overall survival (OS) is clinically crucial and 
has greater importance than RFS. In univariate analyses, 
tests of association between ARID1A.Total, SETD2.
Total, SMARCA2.Total, PBRM1.Truncal, SMARCA4.
Truncal, SMARCA2.Truncal and OS showed p values 
below or near 0.1 (Table 4). They were used for further 
multivariable analysis. With the exception of SMARCA2.
Truncal, all the other biomarker losses showed a 
statistically significant association with OS. It was found 
that losses of SMARCA4.Truncal or SMARCA2.Total 
Figure 1: The Immunohistochemical analysis of ARID1A, PBRM1, SMARCA4, SMARCA2, SETD2 in ccRCC 
foci. Representative foci stained for different markers showing scores of 2, 1, 0 (left, middle, and right). The staining of stromal and 
immunological cells serves as internal positive controls.
Table 2: Summary of protein expression losses in ccRCC tumors
Tumors with protein expression loss Foci with protein expression loss 
PBRM1 31% (49/160) 17% (108/638)
ARID1A 51% (81/160) 32% (202/638)
SETD2 14% (23/160) 6.1% (39/638)
SMARCA4 15% (24/160) 6.9% (44/638)
SMARCA2 38% (61/160) 22% (143/638)
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were associated with significantly better prognosis for 
patients (hazard ratio of 2.55 and 3.59 respectively), while 
losses of ARID1A.Total, PBRM1.Truncal, or SETD2.Total 
were associated with worse prognosis (hazard ratio of 
0.23, 0.42, and 0.3 respectively). Truncal loss counts only 
the cases with truncal protein expression losses, while the 
Total loss includes all the tumors with protein expression 
losses. The Kaplan-Meier curves showed the same trends 
(Figure 4). 
In order to further analyze our data, classification 
and regression trees (CART) methodology was applied 
to construct decision trees with multivariable analyses. 
RFS analysis revealed that patients whose SMARCA2.
Truncal staining was negative (≤ 0) had significantly 
longer recurrence free survival than patients with 
positive SMARCA2 staining (Figure 5A). OS analysis 
revealed that patients whose SMARCA2.Truncal and 
PBRM1.Truncal staining were both negative showed 
the worst overall survival while those with negative 
SMARCA2.Truncal staining and positive PBRM1.
Truncal staining showed the best overall survival 
(Figure 5B). 
Figure 2: The truncal loss analysis revealed hidden links between protein loss and tumor stages. (A) How a phylogenetic 
tree was constructed. A: ARID1A loss; M: SMARCA2 loss; P: PBRM1 loss, G: SMARCA4 loss; S: SETD2 loss. (B) Truncal losses of the 
markers at each stage, either alone or in combination, were presented. (C) Fisher’s exact tests were performed to calculate the p values of 
the associations between the protein marker losses and stages.
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DISCUSSION
The loss of protein expression of important cancer 
genes can occur in a branched fashion or linear fashion in 
different parts of the same tumor (Figure 6). The branched 
fashion occurs in the vast majority of ccRCC tumors, 
constituting the intratumoral heterogeneity phenomena. 
Intratumoral heterogeneity is one of the major reasons 
that cancers are hard to eradicate. A major trend in cancer 
therapies, precision medicine, based upon the notion that 
the tumors in each person need a few major driving DNA 
mutations for tumorigenesis and tumor maintenance, and 
the drugs that hit the vulnerabilities conferred by such 
mutations will lead to clinical efficacy. This was proven 
Table 3: Univariate and multivariable analyses of indicated biomarker losses and their associations 
with recurrence-free survival
Recurrence-free survival
Univariate analysis All patients (160)
Hazard Ratio (95% CI) p value
ARID1A.Total 0.93 (0.59–1.46) 0.754
SETD2.Total 0.50 (0.28–0.89) 0.017
SMARCA4.Total 1.98 (0.98–4.01) 0.056
SMARCA2.Total 1.83 (1.12–3.0) 0.015
PBRM1.Truncal 0.79 (0.55–1.14) 0.210
SETD2.Truncal 0.72 (0.51–1.02) 0.065
SMARCA4.Truncal 1.85 (1.06–3.23) 0.031
SMARCA2.Truncal 1.79 (1.31–2.46) 0.0002
Multivariable analysis All patients (160)
Hazard Ratio (95% CI) p value
SETD2.Total 0.27 (0.08–0.90) 0.034
SMARCA4.Total 1.63 (0.55–4.82) 0.380
SMARCA2.Total 1.57 (0.74–3.36) 0.244
SETD2.Truncal 1.13 (0.61–2.11) 0.695
SMARCA4.Truncal 1.35 (0.64–2.85) 0.429
SMARCA2.Truncal 1.32 (0.85–2.07) 0.218
The biomarker loss was subjected to multivariable analysis if its p value was below 0.1. CI = confidence interval. 
Figure 3: Kaplan-Meier analysis of recurrent free survival. The survival curves were calculated based on SETD2 staining: 
positive (1) and negative (0). Associated log-rank p value was indicated. n: number of cases.
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true in many cases: Gleevec for chronic myeloid leukemia 
(CML) [21] and gastrointestinal stromal tumors (GIST) 
[22], Gefitinib for non-small cell lung cancer carrying 
hyperactive and mutated EGFR [23], and Vemurafenib for 
melanoma [24]. These drugs do not kill dividing cells non-
discriminately so they tend to be quite effective with mild 
side effects. Unfortunately, in most cases tumors would 
develop drug resistance sooner or later. In a certain tumor, 
ITH could mean that a small percentage of the cancer 
cells do not carry the driving mutations, so over time they 
would grow up after treatment. Alternatively, some cancer 
cells might also harbor other mutations or epigenetic 
changes that render them drug resistant [25]. 
The cost of DNA sequencing prevented it from 
being applied to large-scale analysis of ITH. We show 
that IHC analysis can describe ITH at a large scale [14]. 
With the result we first examined whether ITH is useful 
in finding correlations between protein losses and high 
tumor stage. For ARID1A and SETD2, the statistically 
significant associations between marker losses and tumor 
stages would have been missed if truncal loss analysis 
were not performed (Figure 2). Thus the ITH analysis is 
useful here. However, it is highly likely that many tumor-
derived mutations in the cancer genes, especially the 
point mutations, do not lead to protein expression loss, so 
mutational analysis will improve the sensitivity of analysis.
Next we examined the links between marker losses 
and recurrence-free survival (RFS). Only SETD2.Total 
showed a statistical meaningful association with RFS, 
and the loss of SETD2 led to shorter RFS (Table 3 and 
Figure 3). Thus these markers are mostly not very useful 
in predicting RFS, and ITH analysis did not help either.
The overall survival (OS) measures how long 
the patients survive after diagnosis. After multivariable 
analysis, ARID1A.Total, SETD2.Total, SMARCA2.Total, 
PBRM1.Truncal and SMARCA4.Truncal all showed 
statistically significant association with OS: the losses of 
ARID1A, SETD2, and PBRM1 were associated with worse 
prognosis for the patients, while the losses of SMARCA4 
and SMARCA2 were associated with better prognosis 
(Table 4). Interestingly, for PBRM1 and SMARCA4, if the 
ITH analysis were not performed, their associations with 
the OS would not have been discovered. Thus ITH analysis 
also unearthed hidden associations between marker losses 
and overall survival.
We also used the CART methodology to perform 
multivariable analyses. The results were consistent with 
PH model results (Tables 3 and 4). Again, ITH analysis 
derived truncal losses were key to derive meaningful 
associations between marker losses and patient survivals 
in this type of association analysis.
ARID1A is a specificity subunit of the SWI/SNF 
chromatin-remodeling complex. Decreased ARID1A 
expression was prevalent, and it was statistically 
associated with shorter patient survivals [26]. Even though 
a very low percentage of ccRCC tumors harbor mutations 
Table 4: Univariate and multivariable analyses of indicated biomarker losses and their associations 
with overall survival
Overall survival
Univariate analysis All patients (160)
Hazard Ratio (95% CI) p value
ARID1A.Total 0.69 (0.44–1.08) 0.104
SETD2.Total 0.50 (0.29–0.87) 0.014
SMARCA4.Total 1.55 (0.82–2.94) 0.182
SMARCA2.Total 1.50 (0.94–2.38) 0.085
PBRM1.Truncal 0.60 (0.42–0.85) 0.004
SETD2.Truncal 0.77 (0.54–1.09) 0.139
SMARCA4.Truncal 1.97 (1.13–3.45) 0.017
SMARCA2.Truncal 1.60 (1.18–2.17) 0.002
Multivariable analysis All patients (160)
Hazard Ratio (95% CI) p value
ARID1A.Total 0.23 (0.09–0.55) 0.001
SETD2.Total 0.30 (0.15–0.58) 0.0003
SMARCA2.Total 3.59 (1.62–7.94) 0.002
PBRM1.Truncal 0.42 (0.29–0.63) 2.45e-05
SMARCA4.Truncal 2.55 (1.38–4.71) 0.003
SMARCA2.Truncal 0.99 (0.66–1.48) 0.948
The biomarker loss was subjected to multivariable analysis if its p value was below 0.1. CI = confidence interval.
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Figure 4: Kaplan-Meier analysis of overall survival. The survival curves were calculated based on biomarker staining: positive (1) 
and negative (0). Associated log-rank p values were indicated. n: number of cases analyzed.
Figure 5: CART. The decision trees and the survival curves are calculated based on staining of indicated biomarkers: positive (> 0) and 
negative (≤ 0). Associated p value was indicated. n: number of cases analyzed. Truncal changes were derived from ITH analysis. (A) CART 
analysis of biomarkers with RFS; (B) CART analysis of biomarkers with OS.
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in ARID1A, the high rate of ARID1A expression loss 
clearly indicates that it plays a critical role in cancer 
biology in ccRCC, and a clever way to take advantage 
of its loss to treat ccRCC is worth serious efforts to 
pursue. Decreased expression of SETD2 was also linked 
to unfavorable prognosis for patients with nonmetastatic 
ccRCC [27]. Both were consistent with our result. 
PBRM1 is another specificity subunit of the SWI/SNF 
complex. The contribution of PBRM1 mutations to the 
clinical outcome of ccRCC patients has been somewhat 
controversial [28–31]. Our analysis strongly suggests that 
PBRM1 loss is enriched at higher tumor stages (Figure 
2) and is strongly associated with worse overall survival 
(Table 4 and Figure 4). SMARCA4 and SMARCA2 are 
two mutually exclusive catalytic subunits of the SWI/
SNF complex. Their protein losses in ccRCC were 
unknown. We found that SMARCA4 and SMARCA2 
had prevalent expression loss in ccRCC tumors (Table 2). 
In both multivariable analyses, the SMARCA2 loss was 
strongly associated with longer patient overall survival. 
In Small Cell Carcinoma of the Ovary, Hypercalcaemic 
Type (SCCOHT) and Non-Small Cell Lung Cancer 
cell cells, SMARCA4 and SMARCA2 acted as tumor 
suppressors [19, 32]. Thus the tumor-promoting functions 
of SMARCA4 and SMARCA2 might be unique to 
ccRCC. Although the oncogenic pathways activated by 
SMARCA4 and SMARCA2 in the absence of PBRM1 
or ARID1A are currently unknown, they can and should 
be identified in ccRCC cells and tumors with PBRM1 or 
ARID1A deficiency. The identification of these oncogenic 
pathways will prove useful to rationally design therapeutic 
strategies to treat ccRCC tumors with PBRM1 or ARID1A 
deficiency.
MATERIALS AND METHODS
Sample preparation and TMA preparation
A protocol approved by Fox Chase Cancer Center 
IACUC committee (IRB#13-810) was used to obtain 
written informed patient consent. Institutional guidelines 
and protocols were strictly followed when all samples 
were collected. 
160 Patients diagnosed with clear cell renal cell 
carcinoma with available archived Paraffin fixed tissue 
were identified from Fox Chase cancer Center kidney 
database. 40 cases from each of the four tumor stages 
(Stage I–IV) were randomly picked. A pathologist 
reviewed all cases. From each tumor, four different areas 
were selected to cover the intratumoral heterogeneity. 
Eight tissue microarray blocks (TMA) were built at Fox 
Chase Cancer Center biorepository facility.
Figure 6: Branched or linear fashions of protein losses in ccRCC tumors. The branched fashion of protein losses can have two 
roots (tumors 1, 3) or one root (tumors 2, 4), but at different parts of the same tumor the protein losses were not uniform, and some protein 
losses were only present in a subset of tumor foci. In the case of linear fashion of protein loss, one or multiple proteins were lost at once in 
one or multiple foci of the tumors (tumors 5, 6).
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Immunohistochemistry and scoring
The Ventana Discovery ULTRA staining platform 
with Discovery CCI (Ventana cat#950-500) was used for 
antigen retrieval. The total application time was 64 minutes. 
Primary immunostaining step utilized antibodies against 
PBRM1 1:50, ARID1A 1:250, SMARCA2 1:50, 
SMARCA4 1:200, SEDT2 1:100 in Ventana Antibody 
Dilution Buffer (Ventana cat #ADB250). The slides 
were incubated for 44 minutes at room temperature. 
Secondary immunostaining was done with a rabbit 
Horseradish Peroxidase (HRP) multimer cocktail (Ventana 
cat#760-500). The immune complexes were developed 
with the ultraView Universal DAB (diaminobenzidine 
tetrahydrochloride) Detection Kit (Ventana cat#760-500). 
After this the slides were washed with a Tris based reaction 
buffer (Ventana cat#950-300) and stained for 8 minutes with 
Hematoxylin II (Ventana cat #790-2208). The antibodies 
used for IHC are: PBRM1 (Bethyl labs, Cat# A301-591A), 
ARID1A (Sigma-Aldrich, Cat# HPA005456), SMARCA2 
(Sigma-Aldrich, Cat# HPA029981), SMARCA4 (Abcam, 
Cat# ab110641), SETD2 (ProSci, Cat# 30-305).
Two pathologists (W.J., T.P.) performed the scoring 
of the stained foci independently. A score of 2 is given if 
greater than 50% of tumor cells were considered positive in 
a focus, 1 if less than 50% but greater than 5% of tumor cells 
were deemed positive, and 0 if less than 5% of tumor cells 
were positive. In the cases where the two pathologists gave 
different scores, they examined the foci together to reach a 
consensus. If one marker is scored as 0 in one focus, then that 
whole tumor is deemed to have a score of 0 for that marker.
Statistical analysis
Categorical variables were compared between groups 
using Fisher’s exact tests. Univariate and multivariable Cox 
proportional hazards (PH) models were used to associate 
overall survival (OS) and recurrence-free survival (RFS) with 
grade, stage and biomarkers of interest. The markers included 
Arid1A.Total, SetD2.Total, SMARCA4.Total, SMARCA2.
Total, PBRM1.Truncal, SetD2.Truncal, SMARCA4.Truncal 
and SMARCA2.Truncal. Estimates of hazard ratio (HR) 
including 95% confidence intervals were computed for 
each variable. Goodness-of-fit of the Cox PH model was 
assessed using Schoenfeld residuals [33]. For variables 
showing a time-varying effect on survival, weighted Cox 
regression methods were used to account for these effects 
by computing average HRs [34]. In addition, multivariable 
analyses were performed by constructing decision trees using 
the classification and regression trees (CART) methodology. 
A decision tree is a logical model represented as a binary 
tree that shows how the value of a response variable such 
as OS or RFS can be predicted by using the values of a set 
of clinical variables and biomarkers. The unified CART 
framework that embeds recursive binary partitioning into 
the theory of permutation tests was used [35]. This approach 
overcomes the problem of over-fitting and selection bias 
towards variables with many possible splits or missing 
values. It utilizes significance testing procedures and results 
in unbiased selection among variables measured at different 
scales. All tests were two-sided and used a Type I Error of 
5% to determine statistical significance. Computations were 
performed in the R statistical language and environment 
using packages survival and party [36].
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